Balchem Q2 sales beat estimates on growth across segments
Balchem Q2 sales beat estimates on growth across segments
Overview
US specialty ingredients maker's fiscal Q2 sales rose 11% yr/yr, beating analyst expectations
Company achieved record sales and earnings in all segments, driven by growth across businesses
Balchem repurchased $29 mln of stock and expanded its credit facility during the quarter
Outlook
Balchem says it remains confident in its long-term growth outlook
Result Drivers
HUMAN NUTRITION GROWTH - Higher sales in nutrients and food ingredients drove record results in Human Nutrition and Health segment
ANIMAL NUTRITION DEMAND - Higher sales in both monogastric and ruminant markets boosted Animal Nutrition and Health segment
SPECIALTY PRODUCTS SALES - Increased sales in performance gases and plant nutrition supported Specialty Products segment growth
Company press release: ID:nGNXxHDrq
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $284 mln | $268.50 mln (3 Analysts) |
Q2 Adjusted EPS | Beat | $1.49 | $1.40 (2 Analysts) |
Q2 EPS |
| $1.39 |
|
Q2 Net Income |
| $44.60 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy"
Wall Street's median 12-month price target for Balchem Corp is $202.50, about 24.4% above its July 30 closing price of $162.73
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 30 three months ago
Reuters Recommended Reads
July 30 - Quaker Houghton Q2 adjusted EPS beats estimates, announces $250 mln buyback
July 30 - Huntsman Q2 revenue beats analyst expectations on higher volumes and pricing
July 30 - Air Products beats quarterly profit estimates, raises annual forecast
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Balchem
See all newsBalchem Corporation reports results for the quarter ended September 30 - Earnings Summary
Nutrition ingredients maker Balchem's Q3 sales edge past estimates
Balchem Corp reports results for the quarter ended June 30 - Earnings Summary
Balchem Q2 sales beat estimates on growth across segments
Brief: Balchem Corp Enters Amendment No. 1 To Credit Agreement On July 24, 2026 - SEC Filing